INTERNATIONAL STANDARD

ISO 5840-3

Redline version compares Second edition to First edition

Cardiovascular implants — Cardiac valve prostheses —

Part 3: Heart valve substitutes implanted by transcatheter techniques

Implants cardiovasculaires — Prothèses valvulaires —

Partie 3: Valves cardiaques de substitution implantées par des techniques transcathéter

Reference number
ISO 5840-3:redline:2021(E)

IMPORTANT

This marked-up version uses the following colour-coding:

Text example 1 — Text has been added (in green)

~~Text example 2~~ — Text has been deleted (in red)

 — Graphic figure has been added

 — Graphic figure has been deleted

1.x ... — If there are changes in a clause/subclause, the corresponding clause/subclause number is highlighted in yellow in the Table of contents

DISCLAIMER

This marked-up version highlights the main changes in this edition of the document compared with the previous edition. It does not focus on details (e.g. changes in punctuation).

This marked-up version does not constitute the official ISO document and is not intended to be used for implementation purposes.

COPYRIGHT PROTECTED DOCUMENT

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Fax: +41 22 749 09 47
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Page

Foreword v

Introduction vi

1 Scope 1

2 Normative references 1

3 Terms and definitions 3

4 Abbreviations 11

5 Fundamental requirements 12

6 Device description 12

6.1 ~~Intended use~~General 12

6.2 Intended use 12

~~6.2~~6.3 Design inputs 12

~~6.2.1~~6.3.1 Operational specifications 12

~~6.2.2~~6.3.2 Performance specifications 14

~~6.2.3~~6.3.3 Implant procedure 15

~~6.2.4~~6.3.4 Packaging, labelling and sterilization 15

~~6.3~~6.4 Design outputs 16

~~6.4~~6.5 Design transfer (manufacturing verification/validation) 16

~~6.5~~6.6 Risk management 16

7 Design verification ~~testing and analysis/design~~and validation 16

7.1 General requirements 16

7.2 *In vitro* assessment 17

7.2.1 General 17

~~7.2.1~~7.2.2 Test conditions, sample selection and reporting requirements 17

~~7.2.2~~7.2.3 Material property assessment 18

~~7.2.3~~7.2.4 ~~Device hydrodynamic~~Hydrodynamic performance assessment 19

~~7.2.4~~7.2.5 Structural performance assessment 21

~~7.2.5~~7.2.6 ~~Additional implant design evaluation requirements~~Design- or procedure-specific testing 23

~~7.2.6~~7.2.7 ~~Delivery system design evaluation requirements~~Device MRI compatibility 25

~~7.2.7 Design-specific testing ..... 27~~

~~7.2.8 Visibility ..... 27~~

~~7.2.9~~7.2.8 Simulated use 27

7.2.9 Human factors and usability assessment 27

7.2.10 ~~Human factors/usability~~Implant thrombogenic and haemolytic potential assessment 27

7.3 Preclinical *in vivo* evaluation 28

7.3.1 General 28

~~7.3.1~~7.3.2 Overall requirements 28

~~7.3.2~~7.3.3 Methods 30

~~7.3.3~~7.3.4 Test report 31

7.4 Clinical investigations 31

7.4.1 General 31

7.4.2 Study considerations 33

7.4.3 Study endpoints 35

7.4.4 Ethical considerations 35

7.4.5 Pivotal studies: Distribution of subjects and investigators 35

~~7.4.2~~7.4.6 Statistical considerations including sample size and duration 36

~~7.4.3~~7.4.7 ~~Distribution of subjects and investigators~~Patient selection criteria 38

~~7.4.4~~7.4.8 ~~Sample size~~Valve thrombosis prevention 39

~~7.4.5 Entry criteria ..... 39~~

~~7.4.6 Duration of the study ..... 39~~

7.4.7 7.4.9 Clinical data requirements ... 40
7.4.8 Clinical investigation report ... 44
Annex A (informative) Rationale for the provisions of this part of ISO 5840 ... 46
Annex B (informative) Examples of transcatheter heart valve substitutes, components and delivery systems ... 49
Annex C (normative) Packaging ... 53
Annex D (normative) Product labels, instructions for use and training ... 54
Annex E (normative) Sterilization ... 57
Annex F A (informative) Valve description Description of the transcatheter heart valve system ... 58
Annex G B (informative) Transcatheter heart valve substitute hazards, associated failure modes and evaluation methods hazard analysis example ... 60
Annex H (informative) *In vitro* test guidelines for paediatric devices ... 65
Annex I (informative) Statistical procedures when using performance criteria ... 69
Annex J (informative) Examples and definitions of some physical and material properties of transcatheter heart valve substitutes and their components ... 70
Annex K (informative) Examples of standards applicable to testing of materials and components of transcatheter heart valve substitutes ... 82
Annex L (informative) Raw and post-conditioning mechanical properties for support structure materials ... 88
Annex M (informative) Corrosion assessment ... 90
Annex N C (informative) Guidelines for verification of hydrodynamic performance — Pulsatile flow testing ... 93
Annex O (informative) Durability testing ... 103
Annex P D (informative normative) Fatigue assessment Requirements for delivery system design and evaluation ... 105
Annex E (informative) Examples of design specific testing ... 112
Annex Q F (informative) Preclinical *in vivo* evaluation ... 114
Annex R G (normative) Adverse event classification during clinical investigation ... 117
Annex S H (informative) Echocardiographic protocol Multimodality imaging of TAVI and TMVI pre, peri and post-implantation assessments — Examples ... 125
Bibliography ... 131

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

~~International Standards are~~The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the ~~rules given in~~editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

~~The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.~~

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

~~ISO 5840-3~~This document was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 285, *Non-active surgical implants,* in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 5840-3:2013), which has been technically revised.

The main changes compared to the previous edition are as follows: the engineering and clinical requirements in the ISO 5840 series have been updated to current specifications and integrated and harmonized across all parts.

A list of all parts in the ISO 5840 series ~~consists of the following parts, under the general title~~can be found on the ~~*Cardiovascular implants — Cardiac valve prostheses*~~ISO website.

~~— *Part 3: Heart valve substitutes implanted by minimally invasive techniques*~~

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

No heart valve substitute is ideal. Therefore, a group of engineers, scientists and clinicians well aware of the problems associated withThis document has been prepared for transcatheter heart valve substitutes and their development has prepared this part of ISO 5840. In several areas, the provisions of this part of ISO 5840 have been deliberately left partially defined so as not to inhibit development and innovation. This part of ISO 5840 specifies types of tests, test methods and requirements for test apparatus. It requires documentation of test methods and results. This part of ISO 5840 deals with those areas that will ensure adequate mitigation of device-associated risks for patients and other users of the device, facilitate quality assurance, aid the cardiac surgeon and cardiologist in choosing a heart valve substitute, and ensure that the device will be presented in a convenient form. This part ofwith emphasis on providing guidance for ISO 5840 emphasizes the need to specify types of *in vitro* testing, preclinical *in vivo* and clinical evaluations as well as to report, reporting of all *in vitr vitro*, preclinical *in vivo*, and clinical evaluations. It describes the labels and labelling and packaging of the device. Such a process involvingThis process *in vitro*, preclinical *in vivo* and clinical evaluations is intended to clarify the required procedures prior to market release and to enable prompt identification and management of any subsequent problemsissues.

With regard to *in vitro* testing and reporting, apart from basic material testing for mechanical, physical, chemical and biocompatibility characteristics, this part of ISO 5840 also covers important hydrodynamic and durability characteristics of transcatheter heart valve substitutes and their delivery systems. This part of ISO 5840 does not specify exact test methods for hydrodynamic and durability testing but it offers guidelines for the test apparatus.

This part of ISO 5840 should be revised, updated and amended as knowledge and techniques in heart valve substitute technology improve.

This part of ISO 5840document is to be used in conjunction with ISO 5840:2005-1, which will be replaced by and ISO 5840-12 in future.

Cardiovascular implants — Cardiac valve prostheses —

Part 3: Heart valve substitutes implanted by transcatheter techniques

1 Scope

This document is applicable to all devices intended for implantation as a transcatheter heart valve substitute.

This document is applicable to transcatheter heart valve substitutes and to the accessory devices, packaging and labelling required for their implantation and for determining the appropriate size of heart valve substitute to be implanted.

This ~~part of ISO 5840 outlines~~document establishes an approach for verifying/validating the design and manufacture of a transcatheter heart valve substitute through risk management. The selection of appropriate verification/validation tests and methods are to be derived from the risk assessment. The tests can include those to assess the physical, chemical, biological and mechanical properties of heart valve substitutes and of their materials and components. The tests can also include those for preclinical *in vivo* evaluation and clinical evaluation of the finished heart valve substitute.

This ~~part of ISO 5840~~document defines operational conditions and performance requirements for transcatheter heart valve substitutes where adequate scientific and/or clinical evidence exists for their justification.

This ~~part of ISO 5840 is applicable to all devices intended for implantation in human hearts as~~document includes considerations for implantation of a transcatheter heart valve substitute: inside a pre-existing prosthetic device (e.g. valve-in-valve and valve-in-ring configurations).

~~This part of ISO 5840 is applicable to both newly developed and modified transcatheter heart valve substitutes and to the accessory devices, packaging and labelling required for their implantation and for determining the appropriate size of heart valve substitute to be implanted.~~

~~This part of ISO 5840 excludes heart valve substitutes designed for implantation in artificial hearts or heart assist devices.~~

~~This part of ISO 5840 excludes valve-in-valve configurations and homografts.~~

~~This part of ISO 5840 does not specifically address non-traditional surgically implanted heart valve substitutes (e.g. sutureless). For these devices, the requirements of both this part of ISO 5840 and ISO 5840:2005 might be relevant and can be considered.~~

~~NOTE A rationale for the provisions of this part of ISO 5840 is given in Annex A.~~

2 Normative references

The following ~~referenced~~ documents are ~~indispensable for the application of~~referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO ~~10993~~5840-1:2021, ~~*Biological evaluation of medical devices*~~*Cardiovascular implants — Cardiac valve prostheses — Part 1: ~~Evaluation and testing within a risk management process~~General requirements*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

~~ISO 11135-1, *Sterilization of health care products — Ethylene oxide — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*~~

~~ISO/TS 11135-2, *Sterilization of health care products — Ethylene oxide — Part 2: Guidance on the application of ISO 11135-1*~~

~~ISO 11137-1, *Sterilization of health care products — Radiation — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*~~

~~ISO 11137-2, *Sterilization of health care products — Radiation — Part 2: Establishing the sterilization dose*~~

~~ISO 11137-3, *Sterilization of health care products — Radiation — Part 3: Guidance on dosimetric aspects*~~

~~ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*~~

~~ISO 11607-2, *Packaging for terminally sterilized medical devices — Part 2: Validation requirements for forming, sealing and assembly processes*~~

ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*

~~ISO 14160, *Sterilization of health care products — Liquid chemical sterilizing agents for single-use medical devices utilizing animal tissues and their derivatives — Requirements for characterization, development, validation and routine control of a sterilization process for medical devices*~~

ISO 14630~~:2012~~, *Non-active surgical implants — General requirements*

~~ISO 14937, *Sterilization of health care products — General requirements for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process for medical devices*~~

ISO 14971, *Medical devices — Application of risk management to medical devices*

~~ISO 17665-1, *Sterilization of health care products — Moist heat — Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*~~

~~ISO 22442-1, *Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management*~~

~~ISO 22442-2, *Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling*~~

~~ISO 22442-3, *Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents*~~

~~ISO/IEC 17025, *General requirements for the competence of testing and calibration laboratories*~~

IEC 62366 (all parts), *Medical devices — Application of usability engineering to medical devices*

~~ASTM F2052, *Standard test method for measurement of magnetically induced displacement force on medical devices in the magnetic resonance environment*~~

~~ASTM F2503, *Standard practice for marking medical devices and other items for safety in the magnetic resonance environment*~~

~~ASTM F2213, *Standard test method for measurement of magnetically induced torque on medical devices in the magnetic resonance environment*~~

~~ASTM F2182, *Standard test method for measurement of radio frequency induced heating near passive implants during magnetic resonance imaging*~~

~~ASTM F2119, *Standard test method for evaluation of MR image artifacts from passive implants*~~

3 Terms and definitions

For the purposes of this document, the ~~following~~ terms and definitions given in ISO 5840-1:2021 and the following apply.

~~NOTE Additional definitions can be found in the informative annexes.~~

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

— ISO Online browsing platform: available at https://www.iso.org/obp

— IEC Electropedia: available at http://www.electropedia.org/

3.1
~~accessories~~acute assessment
~~device-specific tools that are required to assist~~intra-procedural and immediate post-procedural results used to assess *in ~~the implantation of the transcatheter heart valve substitute~~vivo* safety and performance

Note 1 to entry: All animals entered into acute, short-term assessment will remain under general anaesthesia for the duration of the study.

~~**3.2**~~
~~**adverse event**~~
~~**AE**~~
~~untoward medical occurrence in a study subject which does not necessarily have to have a causal relationship with study treatment~~

~~Note 1 to entry: An AE can be an unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease, temporary or permanent, whether or not related to the prosthetic valve implantation or procedure.~~

~~**3.3**~~
~~**arterial end diastolic pressure**~~
~~minimum value of the arterial pressure during diastole~~

~~**3.4**~~
~~**arterial peak systolic pressure**~~
~~maximum value of the arterial pressure during systole~~

~~**3.5**~~
~~**back pressure**~~
~~differential pressure applied across the valve during the closed phase~~

~~**3.6**~~
~~**body surface area**~~
~~A_{bs}~~
~~total surface area (m^2) of the human body~~

~~Note 1 to entry: This can be calculated (Mosteller's formula) as the square root of product of the weight in kg times the height in cm divided by 3 600 (see Reference[12]).~~

~~**3.7**~~
~~**cardiac index**~~
~~cardiac output (CO, l/min) divided by the body surface area (A_{bs}, m^2), in units l/min/m^2~~

~~**3.8**~~
~~**closing volume**~~
~~portion of the regurgitant volume that is associated with the dynamics of the valve closure during a single cycle~~

~~Note 1 to entry: See Figure 1.~~



Key

X	time
Y	flowrate
1	closing volume
2	leakage volume

Figure 1 — Schematic representation of flow waveform and regurgitant volumes for one cycle

3.9
coating
thin-film material that is applied to an element of a heart valve substitute to modify its physical or chemical properties

3.10
compliance
relationship between change in diameter and change in pressure of a deformable tubular structure (e.g. valve annulus, aorta, conduit), defined in this part of ISO 5840 as

$$C = 100\% \times \frac{(r_2 - r_1) \times 100}{r_1 \times (p_2 - p_1)}$$

where

C is the compliance in units of % radial change/100 mmHg;

p_1 is the diastolic pressure, in mmHg;

p_2 is the systolic pressure, in mmHg;

r_1 is the inner radius at p_1, in millimetres;

r_2 is the inner radius at p_2, in millimetres.

Note 1 to entry: See ISO 25539-1.

3.113.2
component joining materialchronic assessment
material, such as a suture, adhesive or welding compound, used to assemble the components of a heart valve substitute, thereby becoming part oflong-term results following the procedure used to assess chronic *in vivo*the implant device safety and performance after the animal has recovered from anaesthesia

Note 1 to entry: See examples in Annex BThe endpoints and durations of these studies should be determined by risk analysis.

3.12
cycle
one complete sequence in the action of a heart valve substitute under pulsatile flow conditions

3.13
cycle rate
number of complete cycles per unit of time, usually expressed as cycles per minute (cycles/min)

3.143.3
delivery approach
anatomical access used to deliver the implant to the implant site (e.g. transfemoral, transapical, transeptaltransseptal)

3.153.4
delivery system
catheter or other device based system used to deliver the implant to the implant site

3.16
deployed valve diameter
outer diameter (mm) of the implantable device when deployed within the target implant site in an idealized circular configuration

3.17
device embolization
dislodgement from the intended and documented original position to an unintended and non-therapeutic location

3.18
device failure
inability of a device to perform its intended function sufficient to cause a hazard

3.193.5
device migration
detectable movement or displacement of the deviceheart valve substitute from its original position within the implant site, without position and without device embolization

3.20
effective orifice area
EOA
orifice area that has been derived from flow and pressure or velocity data

3.21
failure mode
mechanism of device failure

Note 1 to entry: Catastrophic support structure fracture, calcification and prolapse are examples of failure modes.

3.22
follow-up
continued assessment of patients who have received the heart valve substitute

~~**3.23**~~
~~**forward flow volume**~~
~~volume of flow ejected through the test heart valve substitute in the forward direction during one cycle~~

~~**3.24**~~
~~**fracture**~~
~~disruption, under the action of applied stress or strain, of any part of the transcatheter heart valve substitute that was previously intact~~

~~**3.25**~~
~~**heart valve substitute**~~
~~device used to replace the function of a natural valve of the heart~~

~~Note 1 to entry: See examples in Annex B.~~

~~**3.26**~~
~~**imaging modality**~~
~~imaging method used to facilitate delivery and/or retrieval of the implant within the target implant site, as well as to assess valve performance after implantation~~

~~**3.27**~~**3.6**
~~**implant site**~~**loading**
crimping
~~intended site of~~process to affix or attach a transcatheter heart valve substitute ~~deployment~~onto a delivery device and collapse the valve (i.e. reduce its diameter) for insertion via the *delivery system* (3.4) (e.g. catheter), performed either during manufacture or in the clinic

~~**3.28**~~
~~**intended use**~~
~~use of a product, process or service in accordance with the specifications, instructions and information provided by the manufacturer~~

~~**3.29**~~**3.7**
~~**leakage volume**~~**neo-LVOT**
neo-left ventricular outflow tract
~~component of the regurgitant volume that is associated with leakage during closed phase of a valve in a single cycle and is the sum of the transvalvular leakage volume and paravalvular leakage volume~~region between native anterior mitral leaflet/ transcatheter mitral valve implantation (TMVI) and septal wall, proximal to the aortic valve (see Figure 1)



Key

1	TMVI
2	native anterior mitral leaflet
3	neo-LVOT
4	septal wall

Figure 1 — Neo-LVOT formation behind a mitral leaflet

~~Note 1 to entry: The point of separation between the closing and leakage volumes is obtained according to a defined and stated criterion (the linear extrapolation shown in Figure 1 is just an example).~~

~~Note 2 to entry: See Figure 1.~~

~~**3.30**~~
~~**mean arterial pressure**~~
~~time-averaged arithmetic mean value of the arterial pressure during one cycle~~

~~**3.31**~~
~~**mean pressure difference**~~
~~time-averaged arithmetic mean value of the pressure difference across a heart valve substitute during the forward flow phase of the cycle~~

~~**3.32**~~
~~**non-structural valve dysfunction**~~
~~abnormality extrinsic to the transcatheter heart valve substitute that results in valve dysfunction (stenosis, regurgitation or both)~~

~~**3.33**~~
~~**occluder/leaflet**~~
~~component that inhibits back flow~~

~~Note 1 to entry: See examples in Annex B.~~

~~**3.34**~~
~~**paravalvular leakage volume**~~
~~component of the leakage volume that is associated with leakage around the closed heart valve substitute during a single cycle~~

~~**3.35**~~
~~**reference valve**~~
~~heart valve substitute with a known clinical experience used for comparative preclinical and clinical evaluations~~

~~**3.36**~~
~~**regurgitant fraction**~~
~~regurgitant volume expressed as a percentage of the forward flow volume~~

~~**3.37**~~**3.8**
~~**regurgitant volume**~~**neo-sinus**
~~volume of fluid that flows through a heart valve substitute in the reverse direction during one cycle and is the sum of the closing volume and the leakage volume~~region between implanted transcatheter aortic valve leaflet and native aortic leaflet/leaflet of existing bioprosthetic valve (see Figure 2)



Key
1 transcatheter aortic valve implantation (TAVI) leaflet
2 native leaflet
3 neo-sinus
4 native sinus
a The arrow indicates the direction of the forward flow.

Figure 2 — Neo-sinus formation behind an aortic leaflet

~~Note 1 to entry: See Figure 1.~~

~~**3.38**~~**3.9**
repositioning
change in implant position of a partially- or fully--deployed transcatheter heart valve substitute via a transcatheter technique, possibly requiring full or partial recapturing of the device

~~3.39~~3.10
retrieval
removal of a partially- or fully--deployed transcatheter heart valve substitute via a transcatheter technique

~~3.40~~
~~**risk**~~
~~combination of the probability of occurrence of harm and the severity of that harm~~

~~Note 1 to entry: Adapted from ISO 14971.~~

~~3.41~~
~~**risk analysis**~~
~~systematic use of available information to identify hazards and to estimate the associated risks~~

~~Note 1 to entry: Adapted from ISO 14971.~~

~~3.42~~
~~**risk assessment**~~
~~overall process comprising a risk analysis and a risk evaluation~~

~~Note 1 to entry: Adapted from ISO 14971.~~

~~3.43~~
~~**root mean square forward flow**~~
~~**RMS forward flow**~~
~~square root of the integral of the volume flow rate waveform squared during the positive differential pressure interval of the forward flow phase used to calculate EOA~~

~~Note 1 to entry: See Figure 2.~~



~~Key~~
~~1 aortic pressure~~
~~2 left ventricular pressure~~
~~3 aortic flow rate~~
~~a Positive pressure range.~~
~~b Q_{rms} range.~~

~~**Figure 2 — Schematic representation of the positive pressure period of an aortic forward flow interval**~~